| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2024 | REVERAGEN BIOPHARMA, INC. | 155 GIBBS ST | ROCKVILLE | MD | 20850-0394 | MONTGOMERY | USA | R01FD007284 | Vamorolone trial in Becker muscular dystrophy | 000 | 2 | FDA | 12/30/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $601,151 ) |
| | 2024 | 2024 | REVERAGEN BIOPHARMA, INC. | 155 GIBBS ST | ROCKVILLE | MD | 20850-0394 | MONTGOMERY | USA | R01FD007284 | Vamorolone trial in Becker muscular dystrophy | 001 | 2 | FDA | 1/30/2024 | $601,151 |
| | 2024 | 2021 | REVERAGEN BIOPHARMA, INC. | 155 GIBBS ST | ROCKVILLE | MD | 20850-0394 | MONTGOMERY | USA | R01FD007284 | Vamorolone trial in Becker muscular dystrophy | 000 | 1 | FDA | 1/12/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2021 | REVERAGEN BIOPHARMA, INC. | 155 GIBBS ST STE 433 | ROCKVILLE | MD | 20850-0394 | MONTGOMERY | USA | R01FD007284 | Vamorolone trial in Becker muscular dystrophy | 000 | 1 | FDA | 7/19/2023 | $0 |
| | 2023 | 2021 | REVERAGEN BIOPHARMA, INC. | 155 GIBBS ST | ROCKVILLE | MD | 20850-0394 | MONTGOMERY | USA | SB1NS095423 | Commercialization Readiness Pilot (CRP) to maximize vamorolone international labeling and sales | 000 | 6 | NIH | 8/25/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $0 ) |
| | 2022 | 2021 | REVERAGEN BIOPHARMA, INC. | 155 GIBBS ST STE 433 | ROCKVILLE | MD | 20850-0394 | MONTGOMERY | USA | R01FD007284 | Vamorolone trial in Becker muscular dystrophy | 000 | 1 | FDA | 7/22/2022 | $0 |
| | 2022 | 2020 | REVERAGEN BIOPHARMA, INC. | 155 GIBBS ST STE 433 | ROCKVILLE | MD | 20850-0394 | MONTGOMERY | USA | SB1NS095423 | Commercialization Readiness Pilot (CRP) to maximize vamorolone international labeling and sales | 000 | 5 | NIH | 8/29/2022 | $1 |
| | 2022 | 2020 | REVERAGEN BIOPHARMA, INC. | 155 GIBBS ST STE 433 | ROCKVILLE | MD | 20850-0394 | MONTGOMERY | USA | SB1NS095423 | Commercialization Readiness Pilot (CRP) to maximize vamorolone international labeling and sales | 001 | 5 | NIH | 9/7/2022 | -$1 |
| | 2022 | 2018 | REVERAGEN BIOPHARMA, INC. | 155 GIBBS ST STE 433 | ROCKVILLE | MD | 20850-0394 | MONTGOMERY | USA | R41HD094622 | Building an evidentiary case for circulating GHBP as a biomarker for drug-associated stunting of growth | 000 | 1 | NIH | 11/10/2021 | $0 |
| | 2022 | 2017 | REVERAGEN BIOPHARMA, INC. | 155 GIBBS ST STE 433 | ROCKVILLE | MD | 20850-0394 | MONTGOMERY | USA | R44NS095423 | Phase IIa study of VBP15 for Duchenne muscular dystrophy | 000 | 2 | NIH | 9/26/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $2,272,449 ) |
| | 2021 | 2021 | REVERAGEN BIOPHARMA, INC. | 155 GIBBS ST STE 433 | ROCKVILLE | MD | 20850-0394 | MONTGOMERY | USA | R01FD007284 | Vamorolone trial in Becker muscular dystrophy | 001 | 1 | FDA | 9/29/2021 | $0 |
| | 2021 | 2021 | REVERAGEN BIOPHARMA, INC. | 155 GIBBS ST STE 433 | ROCKVILLE | MD | 20850-0394 | MONTGOMERY | USA | R01FD007284 | Vamorolone trial in Becker muscular dystrophy | 000 | 1 | FDA | 9/20/2021 | $600,085 |
| | 2021 | 2021 | REVERAGEN BIOPHARMA, INC. | 155 GIBBS ST STE 433 | ROCKVILLE | MD | 20850-0394 | MONTGOMERY | USA | SB1NS095423 | Commercialization Readiness Pilot (CRP) to maximize vamorolone international labeling and sales | 001 | 6 | NIH | 9/20/2021 | $0 |
| | 2021 | 2021 | REVERAGEN BIOPHARMA, INC. | 155 GIBBS ST STE 433 | ROCKVILLE | MD | 20850-0394 | MONTGOMERY | USA | SB1NS095423 | Commercialization Readiness Pilot (CRP) to maximize vamorolone international labeling and sales | 000 | 6 | NIH | 9/1/2021 | $1,672,364 |
|
| Issue Date FY: 2020 ( Subtotal = $1,680,179 ) |
| | 2020 | 2020 | REVERAGEN BIOPHARMA, INC. | 155 GIBBS ST STE 433 | ROCKVILLE | MD | 20850-0394 | MONTGOMERY | USA | SB1NS095423 | Commercialization Readiness Pilot (CRP) to maximize vamorolone international labeling and sales | 000 | 5 | NIH | 6/22/2020 | $1,680,179 |
| | 2020 | 2019 | REVERAGEN BIOPHARMA, INC. | 155 GIBBS ST STE 433 | ROCKVILLE | MD | 20850-0394 | MONTGOMERY | USA | R44NS095423 | Phase IIa study of VBP15 for Duchenne muscular dystrophy | 000 | 4 | NIH | 4/6/2020 | $0 |
| | 2020 | 2018 | REVERAGEN BIOPHARMA, INC. | 155 GIBBS ST STE 433 | ROCKVILLE | MD | 20850-0394 | MONTGOMERY | USA | R43AR073541 | Establishing a biomarker framework for feasibility studies of vamorolone in vasculitis | 000 | 1 | NIH | 3/28/2020 | $0 |
| | 2020 | 2018 | REVERAGEN BIOPHARMA, INC. | 155 GIBBS ST STE 433 | ROCKVILLE | MD | 20850-0394 | MONTGOMERY | USA | R43AR073547 | Definition of pharmacodynamic biomarkers for juvenile dermatomyositis for clinical trials | 000 | 1 | NIH | 3/28/2020 | $0 |
| | 2020 | 2018 | REVERAGEN BIOPHARMA, INC. | 155 GIBBS ST STE 433 | ROCKVILLE | MD | 20850-0394 | MONTGOMERY | USA | R41HD094622 | Building an evidentiary case for circulating GHBP as a biomarker for drug-associated stunting of growth | 000 | 1 | NIH | 7/10/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $1,609,058 ) |
| | 2019 | 2019 | REVERAGEN BIOPHARMA, INC. | 155 GIBBS ST STE 433 | ROCKVILLE | MD | 20850-0394 | MONTGOMERY | USA | R44NS095423 | Phase IIa study of VBP15 for Duchenne muscular dystrophy | 003 | 4 | NIH | 8/15/2019 | $1,499,060 |
| | 2019 | 2019 | REVERAGEN BIOPHARMA, INC. | 155 GIBBS ST STE 433 | ROCKVILLE | MD | 20850-0394 | MONTGOMERY | USA | R44NS095423 | Phase IIa study of VBP15 for Duchenne muscular dystrophy | 002 | 3 | NIH | 7/19/2019 | $109,999 |
| | 2019 | 2017 | REVERAGEN BIOPHARMA, INC. | 155 GIBBS ST STE 433 | ROCKVILLE | MD | 20850-0394 | MONTGOMERY | USA | R44NS095423 | Phase IIa study of VBP15 for Duchenne muscular dystrophy | 000 | 2 | NIH | 3/5/2019 | $0 |
| | 2019 | 2017 | REVERAGEN BIOPHARMA, INC. | 155 GIBBS ST STE 433 | ROCKVILLE | MD | 20850-0394 | MONTGOMERY | USA | R44NS095423 | Phase IIa study of VBP15 for Duchenne muscular dystrophy | 001 | 2 | NIH | 3/19/2019 | -$1 |
| | 2019 | 2016 | REVERAGEN BIOPHARMA, INC. | 155 GIBBS ST STE 433 | ROCKVILLE | MD | 20850-0394 | MONTGOMERY | USA | R41AI122780 | Effectiveness of VBP15, a dissociative steroidal analogue, on chronic inflammation in a mouse model of multiple sclerosis | 000 | 1 | NIH | 12/28/2018 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $2,106,315 ) |
| | 2018 | 2018 | REVERAGEN BIOPHARMA, INC. | 155 GIBBS ST STE 433 | ROCKVILLE | MD | 20850-0394 | MONTGOMERY | USA | R44NS095423 | Phase IIa study of VBP15 for Duchenne muscular dystrophy | 000 | 3 | NIH | 8/21/2018 | $1,500,000 |
| | 2018 | 2018 | REVERAGEN BIOPHARMA, INC. | 155 GIBBS ST STE 433 | ROCKVILLE | MD | 20850-0394 | MONTGOMERY | USA | R43AR073547 | Definition of pharmacodynamic biomarkers for juvenile dermatomyositis for clinical trials | 000 | 1 | NIH | 6/5/2018 | $225,000 |
| | 2018 | 2018 | REVERAGEN BIOPHARMA, INC. | 155 GIBBS ST STE 433 | ROCKVILLE | MD | 20850-0394 | MONTGOMERY | USA | R43AR073541 | Establishing a biomarker framework for feasibility studies of vamorolone in vasculitis | 000 | 1 | NIH | 6/1/2018 | $178,041 |
| | 2018 | 2018 | REVERAGEN BIOPHARMA, INC. | 155 GIBBS ST STE 433 | ROCKVILLE | MD | 20850-0394 | MONTGOMERY | USA | R41HD094622 | Building an evidentiary case for circulating GHBP as a biomarker for drug-associated stunting of growth | 000 | 1 | NIH | 6/14/2018 | $224,998 |
| | 2018 | 2016 | REVERAGEN BIOPHARMA, INC. | 155 GIBBS ST STE 433 | ROCKVILLE | MD | 20850-0394 | MONTGOMERY | USA | R41AI122780 | Effectiveness of VBP15, a dissociative steroidal analogue, on chronic inflammation in a mouse model of multiple sclerosis | 000 | 1 | NIH | 3/6/2018 | $0 |
| | 2018 | 2015 | REVERAGEN BIOPHARMA, INC. | 155 GIBBS ST STE 433 | ROCKVILLE | MD | 20850-0394 | MONTGOMERY | USA | R41AR068816 | Effectiveness of VBP15, a dissociative steroidal analogue, on inflammation in a mouse model of arthritis | 000 | 1 | NIH | 1/12/2018 | -$21,724 |
|
| Issue Date FY: 2017 ( Subtotal = $1,357,833 ) |
| | 2017 | 2017 | REVERAGEN BIOPHARMA, INC. | 155 GIBBS ST STE 433 | ROCKVILLE | MD | 20850-0394 | MONTGOMERY | USA | R44NS095423 | Phase IIa study of VBP15 for Duchenne muscular dystrophy | 000 | 2 | NIH | 4/6/2017 | $1,496,525 |
| | 2017 | 2014 | REVERAGEN BIOPHARMA, INC. | 155 GIBBS ST STE 433 | ROCKVILLE | MD | 20850-0394 | MONTGOMERY | USA | R41MD008829 | Evaluation of VBP15 a dissociative steroidal analogue on pain and inflammation | 000 | 1 | NIH | 11/29/2016 | -$4,670 |
| | 2017 | 2014 | REVERAGEN BIOPHARMA, INC. | 155 GIBBS ST STE 433 | ROCKVILLE | MD | 20850-0394 | MONTGOMERY | USA | R41DK102235 | Effect of VBP15, a dissociative steroidal analogue, on intestinal epithelial repair processes in inflammatory bowel disease | 000 | 1 | NIH | 1/4/2017 | -$134,022 |
|
| Issue Date FY: 2016 ( Subtotal = $1,749,055 ) |
| | 2016 | 2016 | VALIDUS BIOPHARMA INC | 9700 GREAT SENECA HIGHWAY | ROCKVILLE | MD | 20850 | MONTGOMERY | USA | R41AI122780 | Effectiveness of VBP15, a dissociative steroidal analogue, on chronic inflammation in a mouse model of multiple sclerosis | 000 | 1 | NIH | 3/31/2016 | $253,802 |
| | 2016 | 2016 | VALIDUS BIOPHARMA INC | 9700 GREAT SENECA HIGHWAY | ROCKVILLE | MD | 20850 | MONTGOMERY | USA | R44NS095423 | Phase IIa study of VBP15 for Duchenne muscular dystrophy | 000 | 1 | NIH | 2/10/2016 | $1,495,253 |
|
| Issue Date FY: 2015 ( Subtotal = $225,000 ) |
| | 2015 | 2015 | VALIDUS BIOPHARMA INC | 9700 GREAT SENECA HIGHWAY | ROCKVILLE | MD | 20850 | MONTGOMERY | USA | R41AR068816 | Effectiveness of VBP15, a dissociative steroidal analogue, on inflammation in a mouse model of arthritis | 000 | 1 | NIH | 8/31/2015 | $220,610 |
| | 2015 | 2015 | VALIDUS BIOPHARMA INC | 9700 GREAT SENECA HIGHWAY | ROCKVILLE | MD | 20850 | MONTGOMERY | USA | R41AR068816 | Effectiveness of VBP15, a dissociative steroidal analogue, on inflammation in a mouse model of arthritis | 000 | 1 | NIH | 8/31/2015 | $4,390 |
|
| Issue Date FY: 2014 ( Subtotal = $450,000 ) (Continued on the next page) |
| | 2014 | 2014 | VALIDUS BIOPHARMA INC | 9700 GREAT SENECA HIGHWAY | ROCKVILLE | MD | 20850 | MONTGOMERY | USA | R41DK102235 | Effect of VBP15, a dissociative steroidal analogue, on intestinal epithelial repair processes in inflammatory bowel disease | 000 | 1 | NIH | 9/22/2014 | $225,000 |
|
